Apoferritin encapsulation of cysteine protease inhibitors for cathepsin L inhibition in cancer cells-Reference-Cited by-同舟云学术

Apoferritin encapsulation of cysteine protease inhibitors for cathepsin L inhibition in cancer cells

Published:2019 Issue:63 Volume:9 Page:36699-36706
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Quilles Junior José C.¹²³⁴⁵,Carlos Fernanda dos Reis Rocho⁵⁶⁷⁸,Montanari A.⁵⁶⁷⁸,Leitão Andrei⁵⁶⁷⁸^ORCID,Mignone Viviane W.⁹¹⁰³⁴,Arruda Maria Augusta⁹¹⁰³⁴,Turyanska Lyudmila¹¹³⁴^ORCID,Bradshaw Tracey D.¹²³⁴^ORCID

Affiliation:

1. Centre for Biomolecular Sciences

2. School of Pharmacy

3. University of Nottingham

4. UK

5. Medicinal Chemistry Group (NEQUIMED)

6. São Carlos Institute of Chemistry (IQSC)

7. University of São Paulo

8. Brazil

9. Queen's Medical Centre

10. School of Life Sciences

11. School of Physics and Astronomy

Abstract

Novel apoferritin encapsulated cysteine protease inhibitors are developed with enhanced and selective uptake by cancer cells, and sustained pH-induced release of the agent. The persistent inhibition of cathepsin L is demonstrated in vitro.

Funder

National Centre for the Replacement Refinement and Reduction of Animals in Research

Engineering and Physical Sciences Research Council

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Fundação de Amparo à Pesquisa do Estado de São Paulo

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2019/RA/C9RA07161J

Reference47 articles.